SYNTHROID®, (levothyroxine sodium tablets, USP)

/SYNTHROID®, (levothyroxine sodium tablets, USP)
SYNTHROID®, (levothyroxine sodium tablets, USP)2018-09-06T09:12:40+00:00

Prescription Drug Name:

SYNTHROID®, (levothyroxine sodium tablets, USP)

ID:

c12f402b-f00b-466d-a6ea-862f00f81ec7

Code:

34391-3

DESCRIPTION


id: 140d047e-7faa-4a50-b09c-666b543b1f6f
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

SYNTHROID (levothyroxine sodium tablets, USP) contain synthetic crystalline L-3,3′,5,5′-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is identical to that produced in the human thyroid gland. Levothyroxine (T4) sodium has an empirical formula of C15H10I4N NaO4
H2O, molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown:

CLINICAL PHARMACOLOGY


id: a8d897c7-db88-4f73-859d-1304f383728c
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1

Thyroid hormone synthesis and secretion is regulated by the hypothalamic-pituitary-thyroid axis. Thyrotropin-releasing hormone (TRH) released from the hypothalamus stimulates secretion of thyrotropin-stimulating hormone, TSH, from the anterior pituitary. TSH, in turn, is the physiologic stimulus for the synthesis and secretion of thyroid hormones, L-thyroxine (T4) and L-triiodothyronine (T3), by the thyroid gland. Circulating serum T3 and T4 levels exert a feedback effect on both TRH and TSH secretion. When serum T3 and T4 levels increase, TRH and TSH secretion decrease. When thyroid hormone levels decrease, TRH and TSH secretion increase. The mechanisms by which thyroid hormones exert their physiologic actions are not completely understood, but it is thought that their principal effects are exerted through control of DNA transcription and protein synthesis. T3 and T4 diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. Thyroid hormones regulate multiple metabolic processes and play an essential role in normal growth and development, and normal maturation of the central nervous system and bone. The metabolic actions of thyroid hormones include augmentation of cellular respiration and thermogenesis, as well as metabolism of proteins, carbohydrates and lipids. The protein anabolic effects of thyroid hormones are essential to normal growth and development. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues. Levothyroxine, at doses individualized according to patient response, is effective as replacement or supplemental therapy in hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine is also effective in the suppression of pituitary TSH secretion in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter and, as adjunctive therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer (see INDICATIONS AND USAGE , PRECAUTIONS , and DOSAGE AND ADMINISTRATION ).

INDICATIONS AND USAGE


id: f4a041e3-067d-43dc-9a5e-39d73926d52f
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Levothyroxine sodium is used for the following indications:

CONTRAINDICATIONS


id: b6dbf13f-86b1-4059-bb94-e10cd3b977a4
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Levothyroxine is contraindicated in patients with untreated subclinical (suppressed serum TSH level with normal T3 and T4 levels) or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction. Levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids (see PRECAUTIONS ). SYNTHROID is contraindicated in patients with hypersensitivity to any of the inactive ingredients in SYNTHROID tablets (See DESCRIPTION – Inactive Ingredients ).

ADVERSE REACTIONS


id: 31a05a1f-b0c2-4d7b-bee3-88d9bc9e13aa
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

Adverse reactions associated with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdosage (see PRECAUTIONS and OVERDOSAGE ). They include the following:

Overdosage


id: b55a1a73-e46f-41cb-b183-e89b28abed73
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

The signs and symptoms of overdosage are those of hyperthyroidism (see PRECAUTIONS and ADVERSE REACTIONS ). In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures have occurred in a child ingesting 18 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.

HOW SUPPLIED


id: 1b44900a-2763-4502-a8c9-b343fc8f5e10
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

SYNTHROID (levothyroxine sodium tablets, USP) are round, color coded, scored and debossed with “SYNTHROID” on one side and potency on the other side. They are supplied as follows:

Strength (mcg) Color NDC# for bottles of
90
NDC # for bottles of 100 NDC # for bottles of 1000 NDC # for unit dose cartons of 100
25 orange 0074-4341-90 0074-4341-13 0074-4341-19
50 white 0074-4552-90 0074-4552-13 0074-4552-19 0074-4552-11
75 violet 0074-5182-90 0074-5182-13 0074-5182-19 0074-5182-11
88 olive 0074-6594-90 0074-6594-13 0074-6594-19
100 yellow 0074-6624-90 0074-6624-13 0074-6624-19 0074-6624-11
112 rose 0074-9296-90 0074-9296-13 0074-9296-19
125 brown 0074-7068-90 0074-7068-13 0074-7068-19 0074-7068-11
137 turquoise 0074-3727-90 0074-3727-13 0074-3727-19
150 blue 0074-7069-90 0074-7069-13 0074-7069-19 0074-7069-11
175 lilac 0074-7070-90 0074-7070-13 0074-7070-19
200 pink 0074-7148-90 0074-7148-13 0074-7148-19 0074-7148-11
300 green 0074-7149-90 0074-7149-13 0074-7149-19

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


id: 01829968-c1ce-4b7d-95a7-7a678f48bb03
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4